Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). Treatment based on adaptation of the immune response has revolutionised cancer therapy in recent years. Immunotherapy responds to the unfulfilled therapeutic need of cancer patients. The mobilisation of the immune response using endogenous viral and bacterial nucleic acid sensors and modulation of the tumour microenvironment using cytokines uses the patient’s immune system to fight cancer and create long-term immune memory to prevent recurrence and metastases. Clinical data for available immunotherapy confirm their efficacy and long-term therapeutic effect. The aim of the project is to develop and implement Selvita S.A.'s own activity characterised at the level of Phase I of a candidate for a new generation drug whose action overcomes the reduction of current therapies, giving the chance to safely treat patients with aggressive, therapy-resistant cancers, preferably as a combination with checkpoint inhibitors (such as anti-PD1 antibodies or cytokines). The proposed strategy envisages working on several protein targets in the preclinical phase: Rig-I, HPK1, STING and TREX1 to increase the chance of selecting a clinical candidate with the highest therapeutic potential and thus the greatest chances of success in clinical trials and commercialisation.